Introduction
============

Head and neck cancer (HNC) is a broad term that encompasses epithelial malignancies that arise in the paranasal sinuses, nasal cavity, oral cavity, pharynx, and larynx. HNC is the sixth most common type of cancer, representing \~6% of all cancer cases and accounting for an estimated 650,000 new cases and 350,000 cancer deaths worldwide each year.[@b1-ott-9-2927] Tobacco smoking and alcohol intake are considered the major risk factors for HNC;[@b2-ott-9-2927] however, only a small proportion of smokers and alcohol users develop HNC in their lifetime, suggesting that individual susceptibility might also be a significant factor in disease etiology. The Cancer Genome Atlas profiled 279 head and neck squamous cell carcinomas and provides a comprehensive landscape of the somatic genomic aberrations associated with HNC.[@b3-ott-9-2927]

The gene encoding cytochrome P450 1A1 (*CYP1A1*) maps to chromosome 15 and encodes an aryl hydrocarbon hydrolase that plays a role in the metabolism of the carcinogenic polycyclic aromatic hydrocarbons that are present in tobacco smoke. Previous studies have demonstrated that an amino acid substitution from isoleucine to valine in codon 462 (rs1048943, A4889G) in exon 7 of *CYP1A1* enhances the catalytic activity of the cytochrome P450 1A1 protein[@b4-ott-9-2927],[@b5-ott-9-2927] and influences the risk of several cancers.[@b6-ott-9-2927]--[@b10-ott-9-2927] To date, a number of epidemiological studies that have explored the association between the *CYP1A1* Ile462Val polymorphism and the risk of HNC have been reported.[@b11-ott-9-2927]--[@b44-ott-9-2927] However, the results of these studies have been conflicting rather than conclusive. Thus, we conducted a cumulative meta-analysis of eligible published studies to further evaluate the association between the Ile462Val polymorphism and HNC risk.

Materials and methods
=====================

Literature source and analytical methods
----------------------------------------

We searched the Medline/PubMed, EMBASE, and Web of Science databases for articles published until December 31, 2015, using various combinations of the following keywords in the search parameters: HNC, oral cancer, oral cavity cancer, pharyngeal cancer, laryngeal cancer, *CYP1A1*, cytochrome P450 1A1, rs1048943, polymorphism, and variant. In addition, we manually searched the reference list of relevant publications to identify additional studies.

The selection criteria of the eligible publications included the following: 1) the study that evaluated the *CYP1A1* Ile462Val polymorphism and the risk of HNC; 2) the publication that reported a case--control study or cohort study; 3) the publication that reported all data regarding the genotype of the *CYP1A1* Ile462Val polymorphism that was required to calculate the odds ratio (OR) with a 95% confidence interval (CI); and 4) the study that used controls verified to have no clinical evidence of a malignancy. Accordingly, reviews and publications of overlapping studies were excluded. In the context of publications with overlapping data, those that included more data were preferentially used in the study. In total, 45 published studies evaluating the association between the *CYP1A1* Ile462Val polymorphism and the risk of HNC were identified. We reviewed all the articles in accordance with the criteria defined earlier and excluded nine reviews and two publications with overlapping data. Ultimately, 34 studies were deemed to be eligible for the present study. One additional article[@b45-ott-9-2927] was included in the oral cancer subgroup analysis only.

Data extraction
---------------

Data were extracted, analyzed by two investigators, and entered into an electronic database. The following information was collected from each study: author, year of publication, country, ethnicity, the source of control (hospital-based controls, which mean controls from hospital, and population-based controls, which mean controls from randomly selected healthy individuals), study population size, genotype frequency, and tumor type. The key characteristics of the eligible studies are summarized in [Table 1](#t1-ott-9-2927){ref-type="table"}.

Quantitative data synthesis
---------------------------

A cumulative meta-analysis was performed to assess the association between the *CYP1A1* Ile462Val polymorphism and the risk of HNC.[@b46-ott-9-2927] The Cochrane *Q* statistics test was used to examine heterogeneity.[@b47-ott-9-2927] The data were combined using either a fixed-effects model or a random-effects model depending on the results of the heterogeneity test. The fixed-effects model was applied if no heterogeneity was detected. In all other cases, the random-effects model was applied.[@b47-ott-9-2927] A funnel plot was created to assess publication bias. Begg's test (a linear regression approach used to measure funnel plot asymmetry on the natural logarithm scale of the OR)[@b48-ott-9-2927] was used to evaluate the symmetry of the funnel plot. A sensitivity analysis was conducted in which we sequentially removed each eligible study from the pooled data.[@b46-ott-9-2927] The pooled OR of all the studies evaluated in this meta-analysis was calculated to evaluate the significance of the Ile/Val+Val/Val vs the Ile/Ile genotype in HNC.

All the statistical analyses were conducted using the STATA 10.0 software package (StataCorp LP, College Station, TX, USA). All the tests were two-sided, and a *P*-value of ≤0.05 was considered to be statistically significant.

Results
=======

Meta-analysis databases
-----------------------

[Table 1](#t1-ott-9-2927){ref-type="table"} lists some general information associated with the eligible studies, including the first author, year of publication, country, ethnicity of the patients, source of controls, tumor subtype, and study population size. We identified a total of 34 studies that included 6,367 cases and 6,395 controls that evaluated the association between the *CYP1A1* Ile462Val polymorphism and the risk of HNC.

Test of heterogeneity
---------------------

No heterogeneity was observed for the *CYP1A1* Ile/Val+Val/Val genotype vs the Ile/Ile genotype in the subgroup analyses of patients with pharyngeal cancer and Caucasian patients. Therefore, we calculated the pooled ORs for these two groups using the fixed-effects model. The random-effects model was used to calculate the pooled OR for the remaining subgroup analyses.

Quantitative data synthesis
---------------------------

[Table 2](#t2-ott-9-2927){ref-type="table"} lists the pooled ORs associated with the *CYP1A1* Ile462Val polymorphism and the risk of HNC calculated for the 6,367 cases and 6,395 controls evaluated. Overall, we observed an increased risk of HNC in patients with the Ile/Val+Val/Val genotype compared to those with the Ile/Ile genotype, with a pooled OR of 1.284 (95% CI: 1.119--1.473; [Figure 1](#f1-ott-9-2927){ref-type="fig"}).

In the subgroup analyses of tumor types, we observed an increased risk of laryngeal cancer and pharyngeal cancer in patients with the Ile/Val+Val/Val genotype compared to those with the Ile/Ile genotype. The pooled ORs for laryngeal cancer and pharyngeal cancer were 1.362 (95% CI: 1.102--1.685) and 1.519 (95% CI: 1.253--1.843), respectively ([Table 2](#t2-ott-9-2927){ref-type="table"}). No significant association between the *CYP1A1* Ile462Val polymorphism and the risk of oral cancer was observed. The pooled OR associated with the risk of oral cancer was 1.181 (95% CI: 0.930--1.500; [Table 2](#t2-ott-9-2927){ref-type="table"}).

In the subgroup analyses of patients stratified by ethnicity, we observed an increased risk of HNC in Asians with the Ile/Val+Val/Val genotype compared to those with the Ile/Ile genotype, with a pooled OR of 1.371 (95% CI: 1.111--1.693; [Table 2](#t2-ott-9-2927){ref-type="table"}). No significant association between the *CYP1A1* Ile462Val polymorphism and the risk of HNC in Caucasians was observed. The pooled OR in this subgroup was 1.138 (95% CI: 0.941--1.376; [Table 2](#t2-ott-9-2927){ref-type="table"}).

In the subgroup analysis in which the data were stratified according to the source of controls used in the study, we observed an increased risk of HNC associated with the Ile/Val+Val/Val genotype compared to those with the Ile/Ile genotype in patients from studies that used hospital-based controls (OR =1.329, 95% CI: 1.138--1.551), but no significant association was observed in patients from studies that used population-based controls (OR =1.013, 95% CI: 0.606--1.694; [Table 2](#t2-ott-9-2927){ref-type="table"}).

Bias diagnosis
--------------

The publication bias was evaluated using a funnel plot analysis. The shape of the funnel plot appeared roughly symmetrical ([Figure 2](#f2-ott-9-2927){ref-type="fig"}), and the results of Begg's test suggested that publication bias would not significantly affect the summary estimates.

Sensitivity analysis
--------------------

To determine the impact of the individual data sets on the pooled OR, we conducted a sensitivity analysis in which each eligible study was consecutively omitted from the pooled data. The pooled OR was not significantly affected by the sequential deletion of individual studies, indicating that the results of this study are reliable and robust ([Figure 3](#f3-ott-9-2927){ref-type="fig"}).

Discussion
==========

Although two previously published meta-analyses evaluated the association between the *CYP1A1* Ile462Val polymorphism and the risk of HNC,[@b49-ott-9-2927],[@b50-ott-9-2927] careful examination of these data reveals several key issues worth noting. First, Qin et al mistakenly included a study published by Cascorbi et al[@b51-ott-9-2927] that evaluated the association between the −463G/A variant of the myeloperoxidase gene and the risk of cancer of the aerodigestive tract in their meta-analysis (supplemental [Table 1](#t1-ott-9-2927){ref-type="table"} and supplemental references in the study of Qin et al[@b50-ott-9-2927]). Similarly, Qin et al also mistakenly included a study published by Bufalo et al[@b52-ott-9-2927] that evaluated the association between the *CYP1A1* Ile462Val polymorphism and the susceptibility of thyroid cancer in their meta-analysis (supplemental [Table 1](#t1-ott-9-2927){ref-type="table"} and supplemental references in Qin et al[@b50-ott-9-2927]). Furthermore, Qin et al[@b50-ott-9-2927] included one article with overlapping data.[@b53-ott-9-2927]

In the second meta-analysis, Liu et al[@b49-ott-9-2927] reported data from a study by Katoh et al[@b14-ott-9-2927] that were inconsistent with the data reported by Katoh et al[@b14-ott-9-2927] in their original publication. Katoh et al reported that they evaluated 92 cases and 147 controls (Table 3 in Katoh et al[@b14-ott-9-2927]); however, Liu et al reported that 147 cases and 92 controls had been evaluated in that study ([Table 1](#t1-ott-9-2927){ref-type="table"} in Liu et al[@b49-ott-9-2927]). Similarly, Liu et al reported that Reszka et al's study evaluated 151 controls ([Table 1](#t1-ott-9-2927){ref-type="table"} in Liu et al[@b49-ott-9-2927]), whereas Reszka et al reported that they evaluated 145 controls ([Table 2](#t2-ott-9-2927){ref-type="table"} in Reszka et al[@b32-ott-9-2927]). Furthermore, Liu et al[@b49-ott-9-2927] reported that the study by McWilliams et al[@b16-ott-9-2927] evaluated 160 cases and 149 controls ([Table 1](#t1-ott-9-2927){ref-type="table"} in Liu et al[@b49-ott-9-2927]). However, McWilliams et al reported that they evaluated 139 cases and 121 controls (Table 4 in McWilliams et al[@b16-ott-9-2927]). In addition, three eligible articles[@b12-ott-9-2927],[@b13-ott-9-2927],[@b27-ott-9-2927] were not included in the study by Liu et al.[@b49-ott-9-2927] Finally, although Sato et al reported that the *CYP1A1* Ile462Val polymorphism was associated with an increased risk of oral cancer,[@b18-ott-9-2927] these data were not included in the oral cancer subgroup analysis in the Liu et al's study ([Figure 2A](#f2-ott-9-2927){ref-type="fig"} in Liu et al[@b49-ott-9-2927]).

Together, these observations indicate that current data describing the association between the *CYP1A1* Ile462Val polymorphism and the risk of HNC are not entirely reliable. Three recent studies[@b41-ott-9-2927],[@b43-ott-9-2927],[@b44-ott-9-2927] on this topic have been subsequently published; however, further verification of the association between the *CYP1A1* Ile462Val polymorphism and the risk of HNC is still required. The cumulative meta-analysis reported here was conducted to verify the association of the *CYP1A1* Ile462Val polymorphism with the risk of HNC using data from a total of 34 studies that evaluated 6,367 cases and 6,395 controls. The goal of this study was to provide comprehensive and conclusive evidence regarding the association of the *CYP1A1* Ile462Val polymorphism with the risk of HNC. Overall, we observed an increased risk of HNC in patients with the Ile/Val+Val/Val genotype compared to those with the Ile/Ile genotype. We also observed an increased risk of HNC in patients with the Ile/Val+Val/Val genotype compared to those with the Ile/Ile genotype in various subgroups (laryngeal cancer, pharyngeal cancer, Asians, and patients in studies that used hospital-based controls).

The potential limitations of this meta-analysis should also be acknowledged. First, only published articles were selected in this study; therefore, publication bias might have influenced the results. To address this issue, we evaluated the eligible studies using Begg's test and determined that the likelihood of publication bias was negligible. Second, although some confounding variables were well balanced between studies, different studies might have used different inclusion criteria and different sources of controls. These factors should be taken into account when interpreting the pooled data. To address this issue, we conducted subgroup analyses of patients in studies that used hospital-based controls and those that used population-based controls. Third, this cumulative meta-analysis is based on an unadjusted estimate; therefore, a more precise analysis accounting for adjusted factors should be carried out in the future.

Conclusion
==========

Our results suggest that the *CYP1A1* Ile462Val polymorphism is associated with an increased risk of HNC, particularly in laryngeal cancer and pharyngeal cancer. The verification of our findings requires additional well-designed studies evaluating large sample sizes.
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###### 

Characteristics of the selected studies

  First author                          Year   Country                      Ethnicity   Source of controls   Tumor type                                Cases   Controls
  ------------------------------------- ------ ---------------------------- ----------- -------------------- ----------------------------------------- ------- ----------
  Park et al[@b11-ott-9-2927]           1997   USA                          Mixed       HB                   Oral and laryngeal cancers                131     131
  Matthias et al[@b12-ott-9-2927]       1998   Germany                      Caucasian   HB                   Oral, laryngeal, and pharyngeal cancers   380     193
  Oude Ophuis et al[@b13-ott-9-2927]    1998   the Netherlands              Mixed       HB                   Oral, laryngeal, and pharyngeal cancers   185     207
  Katoh et al[@b14-ott-9-2927]          1999   Japan                        Asian       HB                   Oral cancer                               92      147
  Morita et al[@b15-ott-9-2927]         1999   Japan                        Asian       HB                   Oral, laryngeal, and pharyngeal cancers   145     164
  McWilliams et al[@b16-ott-9-2927]     2000   USA                          Caucasian   PB                   Oral, laryngeal, and pharyngeal cancers   139     121
  Olshan et al[@b17-ott-9-2927]         2000   USA                          Mixed       HB                   Oral, laryngeal, and pharyngeal cancers   171     189
  Sato et al[@b18-ott-9-2927]           2000   Japan                        Asian       PB                   Oral cancer                               142     142
  Ko et al[@b19-ott-9-2927]             2001   Germany                      Caucasian   HB                   Oral, laryngeal, and pharyngeal cancers   312     300
  Sreelekha et al[@b20-ott-9-2927]      2001   India                        Asian       HB                   Oral cancer                               98      60
  Hahn et al[@b21-ott-9-2927]           2002   Germany                      Caucasian   HB                   Oral cancer                               94      92
  Kao et al[@b22-ott-9-2927]            2002   People's Republic of China   Asian       HB                   Oral cancer                               106     146
  Gronau et al[@b23-ott-9-2927]         2003   Germany                      Caucasian   HB                   Oral, laryngeal, and pharyngeal cancers   187     139
  Gronau et al^45,a^                    2003   Germany                      Caucasian   HB                   Oral cancer                               73      136
  Varzim et al[@b24-ott-9-2927]         2003   Portugal                     Caucasian   HB                   Laryngeal cancer                          88      177
  Evans et al[@b25-ott-9-2927]          2004   USA                          Caucasian   PB                   Oral, laryngeal, and pharyngeal cancers   281     208
  Li et al[@b26-ott-9-2927]             2004   People's Republic of China   Asian       HB                   Laryngeal cancer                          89      164
  Xie et al[@b27-ott-9-2927]            2004   USA                          Mixed       PB                   Oral cancer                               132     143
  Gajecka et al[@b28-ott-9-2927]        2005   Poland                       Caucasian   HB                   Laryngeal cancer                          289     316
  Leichsenring et al[@b29-ott-9-2927]   2006   Brazil                       Mixed       PB                   Oral cancer                               72      60
  Marques et al[@b30-ott-9-2927]        2006   Brazil                       Mixed       HB                   Oral cancer                               231     212
  Sugimura et al[@b31-ott-9-2927]       2006   Japan                        Asian       HB                   Oral cancer                               122     241
  Reszka et al[@b32-ott-9-2927]         2008   Poland                       Caucasian   HB                   Oral, laryngeal, and pharyngeal cancers   127     145
  Sam et al[@b33-ott-9-2927]            2008   India                        Asian       HB                   Oral, laryngeal, and pharyngeal cancers   408     220
  Varela-Lema et al[@b34-ott-9-2927]    2008   Spain                        Caucasian   HB                   Oral and pharyngeal cancers               66      92
  Amtha et al[@b35-ott-9-2927]          2009   Indonesia                    Asian       HB                   Oral cancer                               81      162
  Singh et al[@b36-ott-9-2927]          2009   India                        Asian       HB                   Oral, laryngeal, and pharyngeal cancers   200     200
  Sabitha et al[@b37-ott-9-2927]        2010   India                        Asian       HB                   Oral, laryngeal, and pharyngeal cancers   205     245
  Sharma et al[@b38-ott-9-2927]         2010   India                        Asian       HB                   Oral, laryngeal, and pharyngeal cancers   203     201
  Tai et al[@b39-ott-9-2927]            2010   People's Republic of China   Asian       HB                   Laryngeal and pharyngeal cancers          278     278
  Lourenco et al[@b40-ott-9-2927]       2011   Brazil                       Mixed       HB                   Oral, laryngeal, and pharyngeal cancers   142     142
  Balaji et al[@b41-ott-9-2927]         2012   India                        Asian       HB                   Oral cancer                               157     132
  Szanyi et al[@b42-ott-9-2927]         2012   Hungary                      Caucasian   HB                   Laryngeal and pharyngeal cancers          142     150
  Singh et al[@b43-ott-9-2927]          2014   India                        Asian       HB                   Oral cancer                               122     127
  Maurya et al[@b44-ott-9-2927]         2015   India                        Asian       Unknown              Oral, laryngeal, and pharyngeal cancers   750     749

**Note:**

Included in the oral cancer subgroup analysis only.

**Abbreviations:** HB, hospital-based control study; PB, population-based control study.

###### 

Pooled OR of the association between the *CYP1A1* Ile462Val polymorphism and the risk of head and neck cancer

  Group                Number of studies   Heterogeneity test   Analysis model   Cumulative OR (95% CI)   Hypothesis test        Begg's test                  
  -------------------- ------------------- -------------------- ---------------- ------------------------ ---------------------- ------------- ------- ------ -------
  Overall              34                  104.34               0.000            Random-effects model     1.284 (1.119--1.473)   3.561         0.000   0.36   0.722
  Tumor subtype                                                                                                                                               
   Oral cancer         21                  74.59                0.000            Random-effects model     1.181 (0.930--1.500)   1.364         0.173   0.23   0.820
   Laryngeal cancer    11                  22.44                0.013            Random-effects model     1.362 (1.102--1.685)   2.854         0.004   0.78   0.436
   Pharyngeal cancer   7                   6.82                 0.338            Fixed-effects model      1.519 (1.253--1.843)   4.250         0.000   0.30   0.764
  Ethnicity                                                                                                                                                   
   Asians              16                  59.89                0.000            Random-effects model     1.371 (1.111--1.693)   2.941         0.003   0.14   0.893
   Caucasians          11                  14.98                0.135            Fixed-effects model      1.138 (0.941--1.376)   1.329         0.184   0.00   1.000
  Source of controls                                                                                                                                          
   Population based    5                   14.08                0.007            Random-effects model     1.013 (0.606--1.694)   0.051         0.960   0.73   0.462
   Hospital based      28                  80.64                0.000            Random-effects model     1.329 (1.138--1.551)   3.603         0.000   1.05   0.295

**Abbreviation:** OR, odds ratio.
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